First-In-Patient Trial of a Drug to Treat Kennedy’s Disease First-In-Patient Trial of a Drug to Treat Kennedy’s Disease AnnJi Pharmaceutical Co., Ltd. has launched a first-in-patient Phase 1/2a study of AJ201, a curcumin-based compound, to evaluate its safety, tolerability, and related biochemical and pharmacological activities in Kennedy’s Disease patients. The study will be conducted at

AnnJi Pharmaceutical Co. (AnnJi) has entered into an exclusive license agreement with Avenue Therapeutics Inc. (Avenue, NASDAQ: ATXI) for the development and commercialization of AJ201 in the U.S., Canada, European Union, Great Britain, and Israel for spinal and bulbar muscular atrophy (SBMA), also known as Kennedy’s Disease. Under the terms of the license agreement, AnnJi

AJ201 is being evaluated in a Phase 1b/2a clinical trial in the U.S. for the rare X-linked genetic neurodegenerative disease also known as Kennedy’s Disease which currently has no FDA approved therapy MIAMI, March 02, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the

On December 3rd,2022, AnnJi received  “The National Innovation Award” from the Institute for Biotechnology and Medicine Industry of Taiwan for its new drug development project, AJ201, a Phase 2 stage Nrf2 activator for the treatment of Kennedy’s disease. AnnJi is the only small molecule new drug company among the awardees. Dr. Wendy Huang, the Chair

Dr. Yiumo Michael Chan, VP of Research and Translational Medicine from AnnJi Pharmaceuticals (AnnJi) was invited to speak at 2022 Kennedy’s Disease Association Conference (November 9-11, 2022) held in San Diego, California to introduce the first-in-patient study of AJ201 for the treatment of Kennedy’s Disease, or SBMA. Dr. Chan’s presentation was eagerly anticipated and well

2022 Interdisciplinary Neuroscience Congress organized by Taiwan Neuroscience Alliance (TNA) was held in Linkou Chang Gung Medical Foundation, Taiwan, from September 2 to 4. TNA is gathered 16 neuroscience-related societies, ranging from basic to clinical neuroscience, from computational to cognitive neuroscience, and from technology to therapeutic advances. Its Award Committee awarded the AnnJi representative Dr.